DTC-GPA demonstrates risk stratification for brain metastases in patients with DTC, suggesting improved treatment guidance.
The DTC-GPA is the first validated, disease-specific prognostic tool for patients with brain metastases from DTC. This simple, three-point score offers clinically meaningful risk stratification to guide treatment decisions and prognosis estimation in a rare and heterogeneous patient population.
No takes yet. Share an insight, caveat, or question.
Salim et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: